Overall, these data might facilitate the development of targeted therapies aimed at inhibiting HIF-1α-dependent glycolytic activity in TB-induced immunomodulatory macrophages to ultimately halt HIV-1 dissemination in coinfected patients. This evidence concerns the gene HIF1A and tuberculosis.